These include anti-coagulant drugs to prevent thrombotic and thromboembolic disease; anti-inflammatory agents, such as steroids, interferon α2b, inhibitors of the JAK1/JAK2 kinases and of the Bruton tyrosine kinase; IL-6 or IL-6R inhibitors to neutralize IL-6 activity; anti-angiogenic agents targeting VEGF and angiopoietin 2; and renin-angiotensin-aldosterone system (RAAS) inhibitors. This evidence concerns the gene VEGFA and Thromboembolism.